The Changing Landscape in Renal Cell and Bladder Cancers: Role of Immune Checkpoint Inhibitors
| Overview / Abstract: |
Immune checkpoint inhibitors offer hope for patients with either renal cell carcinoma or bladder cancer who cannot receive platinum-based chemotherapy, or who may not have responded or have stopped responding to traditional chemotherapy regimens. However, identifying the patients who stand to benefit the most from systemic immunotherapy and managing potential, associated adverse events are clinical challenges not well-addressed by existing guidelines. This virtual professorship program is led by expert faculty who speak directly to community oncologists and advance practice clinicians about how to optimally employ these novel therapies in practice in order to improve patient health and outcomes. |
|
Expiration |
Jul 05, 2019 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME, Radiology / RAD Tech CE |
|
Format |
Grand Rounds, Online, Webinar / Webcast / Video |
|
Credits / Hours |
1.00 AMA PRA Category 1 CreditTM |
|
Accreditation |
The University of Texas MD Anderson Cancer Center |
|
Presenters / Authors / Faculty |
Nizar Tannir, MD, FACP |
|
Activity Specialities / Related Topics |
Endocrinology, Family Medicine, Gastroenterology / GI, Immunology / Immunosuppression, Internal Medicine, Managed Care, Oncology / Cancer / Radiation Therapy, Primary Care, Radiology / Imagery / Nuclear Medicine, Urology |
|
Sponsors / Supporters / Grant Providers |
Bristol-Myers Squibb |
|
Keywords / Search Terms |
ACHL Oncology, Bladder, Renal Cell, CME, Nizar Tannir, Matthew Campbell, Cancer, Ipilimumab, Yervoy, Nivolumab, Opdivo, Pembrolizumab, Keytruda, Durvalumab, Imfinzi, Avelumab, Bavencio, Bladder cancer, muscle invasive bladder cancer, Renal cell carcinoma, Immunotherapy, Immuno-oncology, Checkpoint inhibitors, PD-1 receptor inhibition, PD-L1, CTLA-4 inhibition, T cell activation, Immune system targeting of cancer cells Free CE CME |
|